MA29836B1 - Proteines de fusion avec l'albumine - Google Patents
Proteines de fusion avec l'albumineInfo
- Publication number
- MA29836B1 MA29836B1 MA30727A MA30727A MA29836B1 MA 29836 B1 MA29836 B1 MA 29836B1 MA 30727 A MA30727 A MA 30727A MA 30727 A MA30727 A MA 30727A MA 29836 B1 MA29836 B1 MA 29836B1
- Authority
- MA
- Morocco
- Prior art keywords
- fusion proteins
- albumin fusion
- albumin
- vectors
- host cells
- Prior art date
Links
- 102000009027 Albumins Human genes 0.000 title abstract 6
- 108010088751 Albumins Proteins 0.000 title abstract 6
- 102000037865 fusion proteins Human genes 0.000 title abstract 6
- 108020001507 fusion proteins Proteins 0.000 title abstract 6
- 102000039446 nucleic acids Human genes 0.000 abstract 4
- 108020004707 nucleic acids Proteins 0.000 abstract 4
- 150000007523 nucleic acids Chemical class 0.000 abstract 4
- 239000013598 vector Substances 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70752105P | 2005-08-12 | 2005-08-12 | |
| US71238605P | 2005-08-31 | 2005-08-31 | |
| US73272405P | 2005-11-03 | 2005-11-03 | |
| US77691406P | 2006-02-28 | 2006-02-28 | |
| US78136106P | 2006-03-13 | 2006-03-13 | |
| US81018206P | 2006-06-02 | 2006-06-02 | |
| US81368206P | 2006-06-15 | 2006-06-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA29836B1 true MA29836B1 (fr) | 2008-10-03 |
Family
ID=37758042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA30727A MA29836B1 (fr) | 2005-08-12 | 2008-03-07 | Proteines de fusion avec l'albumine |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1924596A4 (ja) |
| JP (1) | JP2009504157A (ja) |
| KR (1) | KR20080071119A (ja) |
| AU (1) | AU2006280312A1 (ja) |
| BR (1) | BRPI0614761A2 (ja) |
| CA (1) | CA2618476A1 (ja) |
| EC (1) | ECSP088262A (ja) |
| IL (1) | IL189246A0 (ja) |
| MA (1) | MA29836B1 (ja) |
| MX (1) | MX2008001865A (ja) |
| NO (1) | NO20081233L (ja) |
| TN (1) | TNSN08064A1 (ja) |
| WO (1) | WO2007021494A2 (ja) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
| US6926898B2 (en) | 2000-04-12 | 2005-08-09 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20080194481A1 (en) * | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
| ES2500918T3 (es) | 2001-12-21 | 2014-10-01 | Human Genome Sciences, Inc. | Proteínas de fusión de albúmina e interferón beta |
| SI1729795T1 (sl) | 2004-02-09 | 2016-04-29 | Human Genome Sciences, Inc. | Albuminski fuzijski proteini |
| EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| EP2474318A1 (en) | 2006-06-07 | 2012-07-11 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| JP2010503396A (ja) * | 2006-09-14 | 2010-02-04 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | アルブミン融合タンパク質 |
| CA2963138C (en) | 2007-01-30 | 2019-05-14 | Epivax, Inc. | Regulatory t cell epitopes, compositions and uses thereof |
| US20110293557A1 (en) | 2008-06-13 | 2011-12-01 | Proyecto De Biomedicina Cima, S.L. | Conjugates for the administration of biologically active compounds |
| BRPI1005159A2 (pt) * | 2009-01-16 | 2018-04-03 | Teva Pharma | "método de tratamento ou prevenção de neutropenia em um paciente humano, método de tratamento ou prevenção de leucopenia em um paciente humano e método de redução da incidência de infecção" |
| EP3243835B1 (en) | 2009-02-11 | 2024-04-10 | Albumedix Ltd | Albumin variants and conjugates |
| KR20100100254A (ko) * | 2009-03-05 | 2010-09-15 | (주)바이오큐어팜 | 인간 혈청 알부민-팀프-2 융합 단백질과 항암제를 포함하는암의 예방 또는 치료용 조성물 |
| EP2470559B1 (en) | 2009-08-24 | 2017-03-22 | Amunix Operating Inc. | Coagulation factor ix compositions and methods of making and using same |
| CA2776241A1 (en) * | 2009-10-30 | 2011-05-05 | Novozymes Biopharma Dk A/S | Albumin variants |
| WO2011124718A1 (en) | 2010-04-09 | 2011-10-13 | Novozymes A/S | Albumin derivatives and variants |
| CA2800173C (en) | 2010-05-21 | 2019-05-14 | Ulrik Nielsen | Bi-specific fusion proteins |
| KR101969526B1 (ko) * | 2011-02-28 | 2019-04-17 | 고쿠리츠켄큐카이하츠호진 고쿠리츠쥰칸키뵤 겐큐센터 | 악성 종양 전이 억제용 의약 |
| GB2491006A (en) | 2011-05-05 | 2012-11-21 | Novozymes Biopharma Uk Ltd | Albumin variants |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| WO2012170969A2 (en) | 2011-06-10 | 2012-12-13 | Biogen Idec Ma Inc. | Pro-coagulant compounds and methods of use thereof |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| AR088463A1 (es) | 2011-10-21 | 2014-06-11 | Abbvie Inc | Metodos para el tratamiento de hcv |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| ES2527544T1 (es) | 2011-10-21 | 2015-01-26 | Abbvie Inc. | Tratamiento mono (PSI-7977) o de combinación con AAD para su uso en el tratamiento del VHC |
| EP2780364A2 (en) | 2011-11-18 | 2014-09-24 | Eleven Biotherapeutics, Inc. | Proteins with improved half-life and other properties |
| LT2804623T (lt) | 2012-01-12 | 2019-12-10 | Bioverativ Therapeutics Inc | Chimeriniai viii faktoriaus polipeptidai ir jų panaudojimas |
| WO2013123457A1 (en) | 2012-02-15 | 2013-08-22 | Biogen Idec Ma Inc. | Recombinant factor viii proteins |
| RS63870B1 (sr) | 2012-02-15 | 2023-01-31 | Bioverativ Therapeutics Inc | Sastavi faktora viii i postupci za pravljenje i upotrebu istih |
| US9944691B2 (en) | 2012-03-16 | 2018-04-17 | Albumedix A/S | Albumin variants |
| CN104519897A (zh) | 2012-06-08 | 2015-04-15 | 比奥根艾迪克Ma公司 | 促凝血化合物 |
| US10202595B2 (en) | 2012-06-08 | 2019-02-12 | Bioverativ Therapeutics Inc. | Chimeric clotting factors |
| CN103525695B (zh) * | 2012-07-04 | 2015-05-20 | 长沙中生众捷生物技术有限公司 | 便携式肾功能检测系统 |
| ES2770501T3 (es) | 2012-07-11 | 2020-07-01 | Bioverativ Therapeutics Inc | Complejo del factor VIII con XTEN y proteína del factor de Von Willebrand y sus usos |
| US10391152B2 (en) | 2012-10-18 | 2019-08-27 | Bioverativ Therapeutics Inc. | Methods of using a fixed dose of a clotting factor |
| US20140128326A1 (en) | 2012-11-08 | 2014-05-08 | Novozymes Biopharma Dk A/S | Albumin variants |
| HRP20231183T1 (hr) | 2013-02-15 | 2024-01-05 | Bioverativ Therapeutics Inc. | Optimizirani gen faktora viii |
| CN105007722A (zh) | 2013-02-16 | 2015-10-28 | 诺维信生物制药丹麦公司 | 药代动力学动物模型 |
| TWI683666B (zh) | 2013-03-15 | 2020-02-01 | 美商百歐維拉提夫治療公司 | 因子ｉｘ多肽調配物 |
| EP4368194A3 (en) | 2013-06-28 | 2024-07-31 | Bioverativ Therapeutics Inc. | Thrombin cleavable linker with xten and its uses thereof |
| TWI667255B (zh) | 2013-08-14 | 2019-08-01 | 美商生物化學醫療公司 | 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途 |
| WO2015048330A2 (en) | 2013-09-25 | 2015-04-02 | Biogen Idec Ma Inc. | On-column viral inactivation methods |
| EP3065769A4 (en) | 2013-11-08 | 2017-05-31 | Biogen MA Inc. | Procoagulant fusion compound |
| SG11201605242YA (en) | 2014-01-10 | 2016-07-28 | Biogen Ma Inc | Factor viii chimeric proteins and uses thereof |
| US11008561B2 (en) | 2014-06-30 | 2021-05-18 | Bioverativ Therapeutics Inc. | Optimized factor IX gene |
| CA3203273A1 (en) | 2014-10-14 | 2016-04-21 | Halozyme, Inc. | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same |
| MA40835A (fr) | 2014-10-23 | 2017-08-29 | Biogen Ma Inc | Anticorps anti-gpiib/iiia et leurs utilisations |
| MA40861A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Anticorps anti-glycoprotéines iib/iiia |
| UA126016C2 (uk) | 2015-08-03 | 2022-08-03 | Біовератів Терапеутікс Інк. | Злитий білок фактора іх |
| BR112018003179A2 (pt) | 2015-08-20 | 2018-09-25 | Albumedix As | conjugados e variantes de albumina |
| CN115960249A (zh) | 2015-10-02 | 2023-04-14 | 银溪制药股份有限公司 | 用于组织修复的双特异性治疗性蛋白质 |
| CN105254766B (zh) * | 2015-10-26 | 2018-10-16 | 中国航天员科研训练中心 | 机械生长因子MGF E domain肽在调控记忆相关基因和miRNA表达中的应用 |
| EP3411478B1 (en) | 2016-02-01 | 2022-06-08 | Bioverativ Therapeutics Inc. | Optimized factor viii genes |
| WO2017189978A1 (en) | 2016-04-28 | 2017-11-02 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| JP2020500306A (ja) | 2016-11-04 | 2020-01-09 | オーフス ウニベルシテット | 新生児Ｆｃ受容体の過剰発現により特徴づけられる腫瘍の同定と治療 |
| EP3548066A1 (en) | 2016-12-02 | 2019-10-09 | Bioverativ Therapeutics Inc. | Methods of treating hemophilic arthropathy using chimeric clotting factors |
| US20200085915A1 (en) | 2016-12-02 | 2020-03-19 | Bioverativ Therapeutics Inc. | Methods of inducing immune tolerance to clotting factors |
| WO2018112362A1 (en) | 2016-12-16 | 2018-06-21 | Biogen Ma Inc. | Stabilized proteolytically activated growth differentiation factor 11 |
| KR20190112763A (ko) | 2017-01-31 | 2019-10-07 | 바이오버라티브 테라퓨틱스 인크. | 인자 ix 융합 단백질 및 이의 제조 및 사용 방법 |
| CN110770251A (zh) * | 2017-04-20 | 2020-02-07 | 诺和诺德股份有限公司 | 纯化白蛋白融合蛋白的方法 |
| KR20200035130A (ko) | 2017-08-09 | 2020-04-01 | 바이오버라티브 테라퓨틱스 인크. | 핵산 분자 및 이의 용도 |
| CA3090136A1 (en) | 2018-02-01 | 2019-08-08 | Bioverativ Therapeutics, Inc. | Use of lentiviral vectors expressing factor viii |
| TW202015723A (zh) | 2018-05-18 | 2020-05-01 | 美商百歐維拉提夫治療公司 | 治療ａ型血友病的方法 |
| MX2021001599A (es) | 2018-08-09 | 2021-07-02 | Bioverativ Therapeutics Inc | Moleculas de acido nucleico y sus usos para la terapia genica no viral. |
| EP3891289A2 (en) | 2018-12-06 | 2021-10-13 | Bioverativ Therapeutics Inc. | Use of lentiviral vectors expressing factor ix |
| US20210113634A1 (en) | 2019-09-30 | 2021-04-22 | Bioverativ Therapeutics Inc. | Lentiviral vector formulations |
| WO2022030580A1 (ja) * | 2020-08-06 | 2022-02-10 | 国立大学法人宮崎大学 | 長時間作用型新規アドレノメデュリン誘導体、その製造方法及びその医薬用途 |
| WO2024080306A1 (ja) * | 2022-10-11 | 2024-04-18 | Ｊｃｒファーマ株式会社 | 血清アルブミンと生理活性を有する蛋白質との融合蛋白質 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2500918T3 (es) * | 2001-12-21 | 2014-10-01 | Human Genome Sciences, Inc. | Proteínas de fusión de albúmina e interferón beta |
| CA2513213C (en) * | 2003-01-22 | 2013-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| SI1729795T1 (sl) * | 2004-02-09 | 2016-04-29 | Human Genome Sciences, Inc. | Albuminski fuzijski proteini |
| US20060051859A1 (en) * | 2004-09-09 | 2006-03-09 | Yan Fu | Long acting human interferon analogs |
-
2006
- 2006-07-31 JP JP2008526056A patent/JP2009504157A/ja not_active Withdrawn
- 2006-07-31 WO PCT/US2006/029391 patent/WO2007021494A2/en active Application Filing
- 2006-07-31 BR BRPI0614761-5A patent/BRPI0614761A2/pt not_active IP Right Cessation
- 2006-07-31 CA CA002618476A patent/CA2618476A1/en not_active Abandoned
- 2006-07-31 MX MX2008001865A patent/MX2008001865A/es not_active Application Discontinuation
- 2006-07-31 EP EP06813242A patent/EP1924596A4/en not_active Withdrawn
- 2006-07-31 AU AU2006280312A patent/AU2006280312A1/en not_active Abandoned
- 2006-07-31 KR KR1020087006077A patent/KR20080071119A/ko not_active Application Discontinuation
-
2008
- 2008-02-04 IL IL189246A patent/IL189246A0/en unknown
- 2008-02-11 TN TNP2008000064A patent/TNSN08064A1/en unknown
- 2008-03-07 MA MA30727A patent/MA29836B1/fr unknown
- 2008-03-10 NO NO20081233A patent/NO20081233L/no not_active Application Discontinuation
- 2008-03-12 EC EC2008008262A patent/ECSP088262A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2618476A1 (en) | 2007-02-22 |
| AU2006280312A1 (en) | 2007-02-22 |
| KR20080071119A (ko) | 2008-08-01 |
| TNSN08064A1 (en) | 2009-07-14 |
| BRPI0614761A2 (pt) | 2009-05-19 |
| WO2007021494A3 (en) | 2007-07-26 |
| NO20081233L (no) | 2008-05-09 |
| EP1924596A2 (en) | 2008-05-28 |
| JP2009504157A (ja) | 2009-02-05 |
| IL189246A0 (en) | 2008-08-07 |
| EP1924596A4 (en) | 2009-07-29 |
| ECSP088262A (es) | 2008-05-30 |
| WO2007021494A2 (en) | 2007-02-22 |
| MX2008001865A (es) | 2008-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA29836B1 (fr) | Proteines de fusion avec l'albumine | |
| EP1841426A4 (en) | TERTIARY CARBINAMINES INCLUDING SUBSTITUTED HETEROCYCLES AS BETA SECRETASE INHIBITORS AND FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| NO20054769L (no) | Substituerte fenylalkansyrer | |
| MX2009002816A (es) | Proteinas de fusion de albumina. | |
| MA31862B1 (fr) | Anticorps anti-mésothéline et leurs utilisations | |
| EA200870019A1 (ru) | Лактамовые соединения и способы их применения | |
| WO2004019878A3 (en) | Adzymes and uses thereof | |
| BRPI0513959A (pt) | anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos | |
| IL195338A (en) | An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use | |
| DE602005021072D1 (de) | Adzyme und deren verwendungen | |
| DE60327999D1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
| TNSN07063A1 (fr) | Utilisations therapeutiques d'inhibiteurs de rtp801 | |
| MA30085B1 (fr) | Traitement du diabete de type 2 avec une association d'un inhibiteur de dpiv et de metformine ou d'une thiazolidinedione | |
| MA30337B1 (fr) | Anticorps | |
| DE602004014117D1 (de) | Thiazole zur verwendung als inhibitoren von protein-kinasen | |
| MX2011006091A (es) | Inhibidores de imidazopirazina syk. | |
| NO20054957L (no) | Subtituerte karboksylsyrer | |
| ATE466580T1 (de) | Azolylaminoazine als proteinkinasehemmer | |
| ATE468336T1 (de) | Azolylaminoazine als proteinkinasehemmer | |
| ATE365733T1 (de) | Zusammensetzungen brauchbar als protein-kinase- inhibitoren | |
| NO20053855D0 (no) | 1-fenylalkankarboksylsyrederivater til behandling av neurodegenerative sykdommer. | |
| MA30041B1 (fr) | Immunoglobulines | |
| TW200505418A (en) | Phenacyl 2-hydroxy-3-diaminoalkanes | |
| WO2006078576A3 (en) | Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease | |
| WO2008127680A3 (en) | Diagnosis and treatment of diseases caused by misfolded proteins |